Development and validation of a prediction model for tube feeding dependence after curative (chemo-) radiation in head and neck cancer

Wopken, Kim; Bijl, Hendrik P.; van der Schaaf, Arjen; Christianen, Miranda E.; Chouvalova, Olga; Oosting, Sjoukje F.; van der Laan, Bernard F. A. M.; Roodenburg, Jan L. N.; Leemans, C. Rene; Slotman, Ben J.

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0094879

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2014

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
https://doi.org/10.1371/journal.pone.0094879

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 28-10-2019
Development and Validation of a Prediction Model for Tube Feeding Dependence after Curative (Chemo-) Radiation in Head and Neck Cancer

Kim Wopken¹*, Hendrik P. Bijl¹, Arjen van der Schaaf¹, Miranda E. Christianen¹, Olga Chouvalova¹, Sjoukje F. Oosting³, Bernard F. A. M. van der Laan⁴, Jan L. N. Roedenburg⁵, C. René Leemans⁶, Ben J. Slotman², Patricia Doornaert⁷, Roel J. H. M. Steenbakkers¹, Irma M. Verdonck-de Leeuw⁶, Johannes A. Langendijk¹

¹ Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, ² Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands, ³ Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, ⁴ Department of Otolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, ⁵ Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, ⁶ Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands

Abstract

Background: Curative radiotherapy or chemoradiation for head and neck cancer (HNC) may result in severe acute and late side effects, including tube feeding dependence. The purpose of this prospective cohort study was to develop a prediction model for tube feeding dependence 6 months (TUBEM6) after curative (chemo-) radiotherapy in HNC patients.

Patients and Methods: Tube feeding dependence was scored prospectively. To develop the multivariable model, a group LASSO analysis was carried out, with TUBEM6 as the primary endpoint (n = 427). The model was then validated in a test cohort (n = 183). The training cohort was divided into three groups based on the risk of TUBEM6 to test whether the model could be extrapolated to later time points (12, 18 and 24 months).

Results: Most important predictors for TUBEM6 were weight loss prior to treatment, advanced T-stage, positive N-stage, bilateral neck irradiation, accelerated radiotherapy and chemoradiation. Model performance was good, with an Area under the Curve of 0.86 in the training cohort and 0.82 in the test cohort. The TUBEM6-based risk groups were significantly associated with tube feeding dependence at later time points (p < 0.001).

Conclusion: We established an externally validated predictive model for tube feeding dependence after curative radiotherapy or chemoradiation, which can be used to predict TUBEM6.


Editor: Richard E. Burney, University of Michigan, United States of America

Received February 13, 2014; Accepted March 14, 2014; Published April 15, 2014

Copyright: © 2014 Wopken et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Dutch Cancer Society (grant no. RUG 2008-3983). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: B. Slotman has received travel support and honorarium from Varian medical systems and BrainLAB AG. All remaining authors have declared no conflicts of interest. The Department of Radiation Oncology of the University of Groningen, University Medical Center Groningen has research agreements with Philips, Elekta, RaySearch and Mirada. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: k.wopken@umcg.nl

Introduction

Patients with head and neck cancer (HNC) often receive intensive anticancer treatment such as radiotherapy as single modality or in combination with chemotherapy and/or targeted agents such as cetuximab. Many patients may have severe difficulties maintaining adequate nutritional intake prior to treatment. This is caused by local tumor growth, which leads to swallowing dysfunction, trismus, odynophagia, dysgeusia and aspiration. In addition, anticancer therapy causes severe side effects such as acute mucositis and xerostomia inducing swallowing dysfunction. After completing such therapy, a substantial proportion of patients without baseline swallowing dysfunction ultimately develop persistent or even progressive swallowing dysfunction. In some cases they require tube feeding for a long period of time [1].

Recently it was shown that swallowing dysfunction has a major impact on health-related quality of life [2]. With grade III–IV swallowing dysfunction according to the RTOG Late Radiation Morbidity Scoring System, the most important general dimensions of health-related quality of life were moderately to severely affected. Moreover, swallowing dysfunction has been associated with psychological distress not only in patients themselves, but also in their spouses [3]. These results demonstrate that swallowing dysfunction in general, and tube feeding dependence in particular, are clinically relevant long-term side effects after curative (chemo-) radiotherapy.
Moreover, high-intensity treatment regimens have resulted in improved survival, but with higher rates of tube feeding dependence in these survivors [4,5]. The prevalence of patients with long-term tube feeding dependence is therefore expected to increase.

Previous studies have shown that the dose to the larynx and pharyngeal musculature in radiotherapy treatment of HNC is associated with the risk of long-term swallowing dysfunction [6–8] and are considered swallowing organs at risk. Advanced radiation delivery techniques such as intensity modulated radiotherapy (IMRT) have been used to reduce the radiation dose to the swallowing organs at risk [9]. Promising results have been reported on the use of swallowing exercises before and during treatment to reduce the risk of persisting swallowing dysfunction after curative (chemo-) radiation [10,11]. Thus, predictive models that can identify patients at increased risk of tube feeding dependence after curative (chemo-) radiotherapy before treatment would allow selection of suitable candidates for preventive strategies, such as swallowing sparing IMRT and/or preventive swallowing exercises.

Therefore, the main purpose of this study was to develop a prediction model for tube feeding dependence after curative (chemo-) radiotherapy in HNC based on pretreatment characteristics that can be used to improve selection of patients, prior to treatment, for these preventive measures and/or support decision making with regard to the treatment strategy in an early stage (e.g. definitive radiotherapy versus primary surgery). This prediction model was validated in an external and independent prospective cohort to further support its general applicability.

**Material and Methods**

**Ethics statement**

All patients were subjected to a prospective data registration program in which complications and treatment results in terms of local control and survival are prospectively assessed. This is done within the framework of routine clinical practice in which outcome and complications are systemically scored as part of a quality assurance program. All data obtained and used for this study has been anonymized.

The (Dutch) Medical Research Involving Human Subjects Act is not applicable to data collection as part of routine clinical practice and use of these data for scientific papers regarding the quality assurance program. Only research that is within the scope of the Medical Research Involving Human Subjects Act needs approval from an (accredited) ethics committee. Therefore, the hospital ethics committee (the Medisch Ethische Toetsingscommissie; METc) concluded that data collection by this program is regarded as part of routine patient care and granted us a waiver from needing ethical approval for the conduct of this study.

In the Netherlands a patient of course has to give his/her consent for the collection of the extra data on behalf of the quality assurance program and the use of these data for scientific papers regarding the quality assurance program. However, according to Dutch legislation, consent is free of form, and verbal consent is sufficient. Therefore, patients were asked to participate in this quality assurance program and asked for permission to use their data for the program and scientific papers regarding the program. Refusal of participation was recorded in their medical record.

**Patients**

The population of this prospective cohort study was composed of 610 consecutive patients with carcinoma of the mucosal surfaces of the larynx, oropharynx, oral cavity, hypopharynx and nasopharynx, who received curative radiotherapy with or without chemotherapy or cetuximab. Data from patients treated at our hospital were used to develop the prediction model (training cohort: 427 patients), while data from patients treated at another hospital were used to externally validate the model (test cohort: 183 patients).

Baseline weight loss was defined as the percentage of total body weight lost during the 6 months prior to radiation, with 1 to 10% weight loss defined as moderate and more than 10% defined as severe weight loss.

As we were primarily interested in radiation-induced swallowing dysfunction, patients that used a feeding tube at baseline were excluded from this analysis (RTOG grade 3–4). Moreover, patients had to be free of local recurrence or distant metastases at the time of assessment of swallowing dysfunction.

**Treatment**

All patients were treated either with conventional 3D conformal radiotherapy (3D-CRT) or IMRT. The dose to the parotid glands was reduced as much as possible. In the cohorts included in this analysis, no dose constraints for the swallowing organs at risk were used.

Patients undergoing concomitant chemoradiotherapy were treated with conventional fractionation (2.0 Gray (Gy) per fraction, 5 times per week up to 70 Gy in 7 weeks). Patients with stage I–II and stage III–IV tumors who were considered ineligible for (chemo-) radiotherapy were treated with accelerated radiotherapy with a concomitant boost technique (2.0 Gy per fraction, 6 times per week up to 70 Gy in 6 weeks). Since 2008, patients with locally advanced (stage III–IV) tumors, for whom chemotherapy was considered infeasible, have been treated with cetuximab using a loading dose of 400 mg/m² one week prior to radiotherapy and a weekly dose of 250 mg/m² during accelerated radiotherapy (2.0 Gy per fraction, 6 times per week up to 70 Gy in 6 weeks).

In the training cohort, concomitant chemoradiotherapy consisted of cisplatin 100 mg/m² on days 1, 22 and 43. In the test cohort, concomitant chemotherapy consisted of 3 cycles of carboplatin (300–350 mg/m²) on day 1 and 5-fluorouracil (5-FU) on days 1 to 4 as a continuous infusion (600 mg/m²/24 hours) every 3 weeks.

At both institutions, prophylactic PEG tube placement was standard of care in all patients treated with curative concomitant chemoradiation and patients were instructed to refrain from using the PEG-tube. In patients with significant weight loss (>5% weight loss in 1 month or >10% in 6 months or BMI <18.5 kg/m²) and/or low nutritional intake (less than half of daily requirements for energy, proteins or fluids) and/or severe swallowing dysfunction prior to treatment, PEG tubes were placed prior to treatment. However, these patients were excluded from the analysis.

Reactive placement of feeding tubes was used for patients with significant weight loss or swallowing dysfunction during treatment; in this situation a nasogastric feeding tube was placed during treatment if swallowing problems were considered temporarily and expected to recover soon. In case of severe swallowing problems early during treatment and/or expected to sustain for a longer period of time, there was a preference for PEG-tube placement.

**Follow up schedule and assessments**

In both hospitals, acute and late radiation-induced side effects were prospectively assessed according to the RTOG/EORTC Acute and Late Radiation Morbidity Scoring System. Tube feeding dependence was scored separately. For the present analysis, the primary endpoint was tube feeding, either with PEG (percutaneous endoscopic gastrostomy) or nasogastric tube at 6 months after completion of treatment (TUBEm6). Patients were
considered tube feeding dependent if a feeding tube was present and used because oral intake was limited or impossible.

Definition of risk groups

The total population of the training cohort was divided into three risk groups based on the risk on TUBEM6. The division into low, intermediate and high risk groups was arbitrary: patients were considered low risk when the probability for TUBEM6 was ≤5%, intermediate risk when this value was >5–15% and high risk for values >15%. To determine whether the model could be extrapolated for the same patients at later time points, the positive and negative predictive values for TUBEM6 were calculated at 12, 18 and 24 months.

Statistics

After the regression analysis, the variance inflation factor was calculated to check for high correlations between candidate prognostic variables. There were no high correlations and, therefore, no changes were made to the variables.

For the development of the prediction model the least absolute shrinkage and selection operator (LASSO) method was used, which is a logistic regression analysis with a bound on the absolute magnitude of the regression coefficients [12]. This method includes all variables in the modeling process but only a subset of predictor variables are eventually included in the model, setting the coefficients of variables that have negligible effects to zero. The LASSO method has been successfully applied to build Normal Tissue Complication (NTCP) models for HNC patients [13].

Model performance was described using different validation measures [14,15]. The discriminating ability of the model was described by the area under the curve (AUC) value based on the Receiver Operating Characteristics curve. The discrimination slope was calculated as the absolute difference between the mean predicted NTCP value for patients with and without the outcome. The calibration of the model reflects the agreement between observed outcomes and predictions. The calibration slope and intercept were calculated as described by Miller et al. [16]. To evaluate whether the model performance measures based on the observed outcomes differed from their expected values, we used Monte-Carlo to generate the expected distributions and calculated p-values. Finally, a Hosmer-Lemeshow test with 10 groups was performed to evaluate the calibration of the model.

Results

Univariate analysis of the training cohort

The training cohort consisted of 427 patients, 77% male and 23% female with a mean age of 62 years. The pretreatment characteristics of the patients are listed in Table 1. Out of 427 patients, 55 (12.9%) were tube feeding dependent at 6 months after completion of treatment. In the univariate analysis, younger age, higher T-classification, higher N-classification, primary tumor site other than the larynx, concomitant chemoradiation, bilateral irradiation, weight loss at baseline and swallowing dysfunction at baseline were significantly associated with TUBEM6 (Table 2).

Group-LASSO analysis in training cohort

The LASSO analysis arrived at a multivariable model containing 5 variables with non-zero coefficients: weight loss prior to treatment, T-classification and N-classification, bilateral irradiation of the neck, and treatment modality, including accelerated radiotherapy and chemoradiotherapy (Table 3).

In individual cases, the risk of TUBEM6 can be estimated using the following equation:

\[
\text{NTCP} = \frac{1}{1 + e^{-S}},
\]

where \(S = -3.69 + (T\text{-stage} * 1.01) + (N\text{-stage} * 0.87) + (\text{moderate weight loss} * 0.82) + (\text{severe weight loss} * 1.51) + (\text{bilateral neck irradiation} * 0.35) + (\text{accelerated radiotherapy} * 0.25) + (\text{chemoradiotherapy} * 0.41)
\]

The risk of TUBEM6 can also be estimated by using the nomogram (Figure 1). In the training cohort, model performance was excellent, with an AUC of 0.86. The discrimination slope had a value of 0.21. The Hosmer-Lemeshow chi square had a value of 9.35 (p-value 0.3) indicating good agreement between expected and observed rates.

External validation

The test cohort consisted of 183 patients, 73% male and 27% female, with a mean age of 62 years. The training and test cohort differed significantly with regard to T-classification, N-classification, the applied treatment modalities and radiation techniques, and weight loss at baseline (Table 1). Out of 183 patients, 27 (14.8%) were tube feeding dependent at 6 months after completion of treatment. Model performance in the external test cohort was good, with an AUC of 0.82 (Expected: 0.80, 95% CI: 0.72–0.86, p-value: 0.8) and a discrimination slope of 0.20 (Expected: 0.19, 95% CI: 0.13–0.25, p-value: 0.6). The calibration graph (Figure S1) illustrates that the observed NTCP-values of TUBEM6 in the test cohort are in close proximity of the predicted NTCP-values. The Hosmer-Lemeshow test showed no statistically significant difference between predicted and measured outcomes in the test cohort (Table S1).

Relationship with tube feeding dependence at subsequent time points

The prevalence of tube feeding dependence was 6.9% (23 of 353 patients at risk) at 12 months (TUBEM12), 3.6% (9 of 251 patients at risk) at 18 months (TUBEM18) and 4.0% (8 of 200 patients at risk) at 24 months (TUBEM24). TUBEM6 was very predictive for tube feeding dependence at later time points. The negative predictive values of TUBEM6 for TUBEM12, TUBEM18 and TUBEM24 were 97.1%, 99.1% and 98.9%, respectively, indicating that almost all patients who were not tube feeding dependent at 6 months remained independent at subsequent time points. The positive predictive values of TUBEM6 for TUBEM12, TUBEM18 and TUBEM24 were
TUBE_2 were 50.0%, 36.8% and 40.0%, respectively, indicating recovery from tube feeding dependence in more than half of the patients.

**Discussion**

The purpose of the current study was to develop and validate a prediction model for tube feeding dependence 6 months after curative (chemo-) radiotherapy in HNC patients. Such a model could be used in clinical practice to predict which patients are at risk for long-term tube feeding dependence, prior to treatment, and would thus be suitable candidates for preventive measures such as swallowing exercises and/or swallowing sparing IMRT.

In the LASSO analysis, five independent prognostic factors for TUBE_2 were identified: advanced T-stage (T3–T4), positive N-stage, weight loss at baseline, bilateral irradiation of the neck, and treatment modality. Model performance in both the training cohort and the test cohort from another hospital was good to excellent, which confirms the generalization ability of the model.

A prediction model as presented in this study is increasingly desirable due to the more aggressive treatment regimens that are being used in HNC, including altered fractionation schedules for radiotherapy, concomitant (chemo-) radiotherapy or both. These intensive cancer treatments have improved loco-regional control and overall survival [17–19] but at the expense of an increase in radiation-induced side effects [20] in particular long-term swallowing dysfunction [21].

Prophylactic feeding tube placement is standard practice in many institutions to avoid treatment interruptions and unplanned...
hospitalizations because of compromised nutritional intake and/or dehydration [22]; adequate nutrition has been shown to improve tolerance and response rates to (chemo-) radiotherapy [23].

However, others have shown that pretreatment feeding tube placement may lead to increased long-term swallowing dysfunction, longer feeding tube duration and the need for pharyngo-esophageal dilatation [24]. In addition, long-term feeding tube dependence may significantly reduce quality of life after treatment for HNC [22,25]. Terrell et al. [26] showed that feeding tube dependence was the strongest clinical predictor of negative effects on health-related quality of life relative to other medical co-morbidities. It was associated with significantly lower scores on 10 out of 12 collective domains in the Medical Outcomes Study Short Form 36-item Health Survey and HNC quality-of-life instruments.

As already mentioned, at both institutions, prophylactic PEG tube placement was standard of care in all patients treated with curative concomitant chemoradiation and patients were instructed to refrain from using the PEG-tube. In patients with significant weight loss (>5% weight loss in 1 month or >10% in 6 months or BMI <18.5 kg/m²) and/or low nutritional intake [less than half of daily requirements for energy, proteins or fluids] and/or severe swallowing dysfunction prior to treatment, PEG tubes were placed prior to treatment. However, these patients were excluded from the analysis.

Chemoradiotherapy was a prognostic factor in the LASSO analysis. It should be stressed that given the fact that all patients receiving concomitant chemoradiation received prophylactic PEG tube placement, the Odds ratio of 1.51 should be considered the results of this preset combination and that no conclusions can be drawn with regard to these two factors separately. However, given this Odds ratio of 1.51 and the Odds ratio of 1.28 found for accelerated radiotherapy (without prophylactic PEG-tube placement), we believe that the contribution of prophylactic PEG tube feeding is probably limited or absent.

The training cohort and test cohort were from two different hospitals with different chemotherapy regimens in each hospital. In the training cohort, cisplatinum was used while in the test cohort 5-FU in combination with carboplatin was used. The model performance in both cohorts was comparable, which indirectly confirms that there will probably be no major difference between the two chemotherapy regimens.

Given that both advanced T-stage (larger tumors) and N-stage and bilateral irradiation of the neck were prognostic factors for feeding tube dependence at 6 months after (chemo-) radiotherapy, it can be hypothesized that the risk of tube feeding dependence is

### Table 2. Results of the univariate logistic regression analysis with tube feeding dependence at 6 months (TUBEM6) as primary endpoint in patients included in the training cohort.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Odds ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>1.61 (0.86–3.00)</td>
<td>0.135</td>
</tr>
<tr>
<td>Age</td>
<td>&gt;65 years</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18–65 years</td>
<td>2.32 (1.18–4.54)</td>
<td>0.014</td>
</tr>
<tr>
<td>T-classification</td>
<td>Tis-T2</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T3–T4</td>
<td>10.02 (5.08–19.78)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>N-classification</td>
<td>N0</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N+</td>
<td>7.67 (4.05–14.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Primary site</td>
<td>Larynx</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral cavity</td>
<td>8.63 (2.92–25.51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Oropharynx</td>
<td>8.74 (3.93–19.47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Nasopharynx</td>
<td>6.09 (1.70–21.83)</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>Hypopharynx</td>
<td>9.71 (3.52–26.79)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Treatment modality</td>
<td>Conventional radiotherapy</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Accelerated radiotherapy</td>
<td>1.77</td>
<td>(0.79–3.99)</td>
</tr>
<tr>
<td></td>
<td>Chemoradiation</td>
<td>7.72 (3.38–17.67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Radiation technique</td>
<td>3D-CRT</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IMRT</td>
<td>1.67 (0.76–3.67)</td>
<td>0.202</td>
</tr>
<tr>
<td>Neck irradiation</td>
<td>Local or unilateral irradiation</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bilateral irradiation</td>
<td>15.45</td>
<td>(3.71–64.39)</td>
</tr>
<tr>
<td>Baseline swallowing</td>
<td>Grade 0</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>(grading according to RTOG)</td>
<td>Grade 1–2</td>
<td>3.20 (1.62–6.32)</td>
<td>0.001</td>
</tr>
<tr>
<td>Weight loss</td>
<td>No weight loss</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>(baseline)</td>
<td>1–10%</td>
<td>5.66 (2.93–10.94)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>&gt;10%</td>
<td>16.36 (6.42–41.68)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: 3D-CRT, Three Dimensional Conformal Radiotherapy; IMRT, Intensity-Modulated Radiation Therapy; RTOG, Radiation Therapy Oncology Group; CI, Confidence Interval.
doi:10.1371/journal.pone.0094879.t002
related to the radiation dose distribution in the anatomical structures involved in swallowing, such as the pharyngeal constrictor muscles. A number of authors indeed showed a dose-volume-effect relationships of anatomical structures involved in swallowing and swallowing dysfunction after (chemo-) radiotherapy, such as the pharyngeal constrictor muscles [8,27–29].

Accelerated radiotherapy was also an independent prognostic factor for tube feeding dependence. These results are in line with those presented by Overgaard et al. who showed that accelerated radiotherapy lead to more frequent and longer persisting confluent mucositis than the conventionally treated group and consequently long-term dysphagia [30]. Another more recent updated study, however, showed that accelerated RT does increase acute but not late morbidity, including dysphagia [31].

In the current study, baseline weight loss was also an independent prognostic factor for tube feeding dependence. This

Table 3. Results of the LASSO analysis with tube feeding dependence at 6 months (TUBEM6) as primary endpoint.

<table>
<thead>
<tr>
<th>Variable</th>
<th>B</th>
<th>95% CI of B</th>
<th>OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3–T4 vs. Tis-T2</td>
<td>1.01</td>
<td>(0.79–1.32)</td>
<td>2.75</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>N-classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N+ vs. N0</td>
<td>0.87</td>
<td>(0.65–1.10)</td>
<td>2.39</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Weight loss (baseline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–10% weight loss vs. no weight loss</td>
<td>0.82</td>
<td>(0.65–0.99)</td>
<td>2.27</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>&gt;10% weight loss vs. no weight loss</td>
<td>1.51</td>
<td>(1.19–1.83)</td>
<td>4.53</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Neck irradiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilateral vs. local/unilateral</td>
<td>0.35</td>
<td>(0.06–0.66)</td>
<td>1.42</td>
<td>p = 0.011</td>
</tr>
<tr>
<td>Treatment modality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemoradiation vs. conventional fractionation</td>
<td>0.41</td>
<td>(0.16–0.68)</td>
<td>1.51</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Accelerated fractionation vs. conventional fractionation</td>
<td>0.25</td>
<td>(0.10–0.41)</td>
<td>1.28</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Constant</td>
<td>–3.69</td>
<td>(–4.19––3.21)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: OR, Odds Ratio; CI, Confidence Interval; B, model coefficient beta.
doi:10.1371/journal.pone.0094879.t003

Figure 1. Nomogram for tube feeding dependence to determine normal tissue complication probability (NTCP) values for each individual patient. Abbreviations: SF, conventional radiotherapy; ART, accelerated radiotherapy; CRT, chemoradiation.
doi:10.1371/journal.pone.0094879.g001
is in accordance with a previous report [1] in which baseline weight loss was shown to be an independent prognostic factor for grade 2−4 RTOG swallowing dysfunction at 6 months after treatment. This suggests that a relatively high percentage of baseline swallowing dysfunction is not recognized by radiation oncologists and that swallowing dysfunction is therefore often underreported, even in the case of prospective assessment of toxicity.

From clinical practice we know that the reasons for feeding tube placement are not solely related to swallowing problems, but may be multifactorial. Nausea due to chemotherapy treatment, changes in taste or saliva production and other factors may also necessitate feeding tube placement. We did not directly take these factors into account in this analysis since it was not possible to obtain information about this for each individual patient. This is something, however, that may have influenced feeding tube placement and use in this patient group.

As the main purpose of the current analysis was to develop and validate a multivariable prediction model that can be used to select patients prior to treatment (i.e. during the preparation phase of radiotherapy) for preventive measures, we did not take into account candidate variables related to dose distributions in swallowing organs at risk. This, however, will be investigated in future research.

Our results show that TUBE₆₆₆ after treatment is predictive for tube feeding dependence at later time points up to 24 months after completion of radiotherapy. This is also in accordance with previous reports [1], which showed that swallowing dysfunction at 6 months after curative (chemo-) radiation is highly predictive for swallowing dysfunction at subsequent time points up to several years after treatment.

**References**


